Posters

Early outcomes in patients with persistent diabetic macular edema switched from ranibizumab to intravitreal dexamethasone implant injection therapy

Poster Details

First Author: M.Dogan TURKEY

Co Author(s):    M. Sabaner                             

Abstract Details



Purpose:

To investigate the effect of intravitreal dexamethasone implant injections in patients with persistent diabetic macular edema who were previously injected with multiple intravitreal ranibizumab.

Setting:

Afyon Kocatepe University Faculty of Medicine, Department of Ophthalmology, Afyonkarahisar, Turkey

Methods:

Thirty-six eyes of 24 patients with persistent diabetic macular edema were enrolled to this retrospective study. Patients, poor-responded to previous ranibizumab treatment, were switched to intravitreal dexamethasone implant therapy. Each patient was injected one dose intravitreal dexamethasone implant and examined first, second and third months after. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and spectral domain-optical coherence tomography (SD-OCT) findings such as central macular thickness (CMT), total macular volume (TMV), central subfield volume (CSV) and choroidal thickness (CT) were evaluated.

Results:

The mean age was 64.28±8.60 years. The number of individuals of each sex was equal. 21 (%58) eyes were pseudophakic, 15 (%42) were phakic. During before the switch, patients received a mean of 6.33±1.22 ranibizumab injections. Mean BCVA at baseline was 0.96±0.62 LogMAR. It changed to 0.94±0.63 LogMAR (p=0.881) during switch and 0.89±0.64 LogMAR (p=0.666) at one month after switch. Mean CMT at baseline was 572.36±291.70 µm. It changed to 491.22±228.95 µm (p=0.200) during switch and 223.69±69.65 µm (p<0.001) at one month after switch. Mean TMV at baseline was 11.81±3.21 mm3. It changed to 11.18±2.36 mm3 (p=0.355) during switch and 8.76±0.96 mm3 (p<0.001) at one month after switch. Mean CSV at baseline was 0.44±0.20 mm3. It changed to 0.39±0.14 mm3 (p=0.195) during switch and 0.21±0.04 mm3 (p<0.001) at one month after switch. Mean CT at baseline was 177.00±27.50 µm. It changed to 176.39±27.37 µm (p=0.896) during switch and 176.11±28.15 µm (p=0.864) at one month after switch.

Conclusions:

Intravitreal dexamethasone implant is effective in treatment of persistent diabetic macular edema with anti-VEGF therapy. Intravitreal dexamethasone implant could be considered as part of therapy in those patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy